Novocure earns Japanese approval for tumor-treating fields
September 15, 2025
Novocure (Nasdaq:NVCR) announced today that it received regulatory approval in Japan for its Optune Lua wearable device.
Novocure (Nasdaq:NVCR) announced today that it received regulatory approval in Japan for its Optune Lua wearable device.
Johnson & Johnson MedTech‘s Shockwave Medical announced today that it launched its Javelin peripheral IVL catheter in Europe.
SHENZHEN, China, Sept. 15, 2025 /PRNewswire/ — Shenzhen Sunsred Technology Co., Ltd. is shaking things up in the wellness tech world with its latest lineup of red light therapy devices.
Pulse Biosciences will study PFA in cardiac surgery. Meanwhile, Galvanize Therapeutics also named a new CEO, and PFA pioneer Steven Mickelsen has launched another company.
The finding opens a new path for cancer treatment.
The current step represents a major proof of concept in humans for TruLeaf’s innovative technology aimed at transcatheter replacement of the mitral and tricuspid valves
Nearly 50 new cancer therapies are approved every year. This is good news. “But for patients and their treating physicians, it is becoming increasingly difficult to keep track and to select the treatment methods from which the people affected—each with their very individual tumor characteristics—will benefit the most,” says Dr. Altuna Akalin, head of the Bioinformatics and Omics Data Science technology platform at the Berlin Institute for Medical Systems Biology of the Max Delbrück Center (MDC-BIMSB).
Researchers at Emory Goizueta Brain Health Institute and partner institutions have found new clues in the blood that could help explain why Alzheimer’s disease develops and how it affects memory.
Tumor immunotherapies, especially those leveraging T-cells to identify and eliminate cancer cells, represent a major breakthrough in cancer treatment. However, many tumor-associated antigens are not expressed at a high enough density on the cancer cell surface to effectively activate T-cells, and these antigens are often present at low levels in normal tissues, leading to poor treatment specificity and potential off-target toxic side effects.
MASON, Ohio, Sept. 12, 2025 /PRNewswire/ — Haag-Streit USA, a leading manufacturer and distributor of ophthalmic diagnostic devices, surgical microscopes, and virtual reality-based medical simulators, is proud to announce the launch of two new innovations: the Elara 900 and the Refractor 900. Both products will make their international debut at ESCRS 2025 in Copenhagen and their US debut at the American Academy of Ophthalmology (AAO) annual meeting in October.